CompletedPHASE1, PHASE2NCT00448357

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
UNC Lineberger Comprehensive Cancer Center
Principal Investigator
Thomas C. Shea, MD
UNC Lineberger Comprehensive Cancer Center
Intervention
rabbit anti-thymocyte globulin (ATG)(biological)
Enrollment
54 enrolled
Eligibility
18-55 years · All sexes
Timeline
20052015

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Otsuka America Pharmaceutical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00448357 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials